CAT

904.52

-3.33%↓

329.37

-0.02%↓

GEV.US

900

-4.83%↓

RTX

180.12

+0.41%↑

212.54

-2.89%↓

CAT

904.52

-3.33%↓

329.37

-0.02%↓

GEV.US

900

-4.83%↓

RTX

180.12

+0.41%↑

212.54

-2.89%↓

CAT

904.52

-3.33%↓

329.37

-0.02%↓

GEV.US

900

-4.83%↓

RTX

180.12

+0.41%↑

212.54

-2.89%↓

CAT

904.52

-3.33%↓

329.37

-0.02%↓

GEV.US

900

-4.83%↓

RTX

180.12

+0.41%↑

212.54

-2.89%↓

CAT

904.52

-3.33%↓

329.37

-0.02%↓

GEV.US

900

-4.83%↓

RTX

180.12

+0.41%↑

212.54

-2.89%↓

Home・Aandelen Lijst・Ocugen Inc

Ocugen Inc

Gesloten

1.22 -2.4

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.22

Max

1.3

Belangrijke statistieken
By Trading Economics
Inkomsten	-1.5M -19M
Verkoop	1.7M 1.5M
EPS	-0.06
Winstmarge	-1,250.946
Werknemers	116
EBITDA	-987K -17M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+821.77% upside

Dividenden
By Dow Jones
Volgende Winsten	31 jul 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-162M 464M
Vorige openingsprijs	3.62
Vorige sluitingsprijs	1.22

Ocugen Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 jun 2026, 23:49 UTC

Marktinformatie

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9 jun 2026, 23:45 UTC

Acquisities, Fusies, Overnames

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9 jun 2026, 23:44 UTC

Acquisities, Fusies, Overnames

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9 jun 2026, 23:44 UTC

Acquisities, Fusies, Overnames

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9 jun 2026, 23:43 UTC

Acquisities, Fusies, Overnames

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9 jun 2026, 23:35 UTC

Marktinformatie

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9 jun 2026, 22:06 UTC

Acquisities, Fusies, Overnames

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9 jun 2026, 22:05 UTC

Acquisities, Fusies, Overnames

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9 jun 2026, 22:05 UTC

Acquisities, Fusies, Overnames

Samsung: Additional Investment Makes It Largest Shareholder in Element

9 jun 2026, 22:05 UTC

Acquisities, Fusies, Overnames

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9 jun 2026, 20:51 UTC

Winsten

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9 jun 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

9 jun 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 jun 2026, 20:09 UTC

Marktinformatie

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9 jun 2026, 19:36 UTC

Marktinformatie

Cattle Climbs as Crude Oil Falls -- Market Talk

9 jun 2026, 19:32 UTC

Marktinformatie

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9 jun 2026, 19:25 UTC

Marktinformatie

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9 jun 2026, 19:00 UTC

Marktinformatie

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9 jun 2026, 18:52 UTC

Acquisities, Fusies, Overnames

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9 jun 2026, 18:47 UTC

Marktinformatie

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9 jun 2026, 18:37 UTC

Marktinformatie

Canada's Cooling Trade With the U.S. -- Market Talk

9 jun 2026, 18:27 UTC

Marktinformatie

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9 jun 2026, 17:35 UTC

Marktinformatie

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9 jun 2026, 17:30 UTC

Marktinformatie

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9 jun 2026, 16:34 UTC

Marktinformatie

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9 jun 2026, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

9 jun 2026, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 jun 2026, 16:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Health Care Roundup: Market Talk

9 jun 2026, 15:28 UTC

Marktinformatie

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9 jun 2026, 15:25 UTC

Marktinformatie

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Peer Vergelijking

Prijswijziging

Ocugen Inc Prognose

Koersdoel

By TipRanks

821.77% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 11.43 USD 821.77%

Hoogste 22 USD

Laagste 7 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ocugen Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Gebaseerd op 7 analisten die aandelenratings hebben gegeven aan Ocugen Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.